Do You Believe West Pharmaceutical Services (WST) Represents a Tremendous Opportunity?

Generation Investment Management , an investment management firm, released its "Global Equity Strategy" second quarter 2026 investor letter. The letter can be downloaded here . The letter discusses the challenges of AI-driven market concentration and emphasizes the potential for long-term investors. It notes that the best companies are currently underperforming due to market returns being concentrated in a few stocks, driven by momentum and retail investment. The authors defend their active management strategy with a sustainability focus, asserting that their approach remains valid despite market fluctuations. They differentiate between cyclical and structural underperformance, suggesting the current market conditions reflect the former. The letter argues for the value of investing in quality, sustainable companies that the market may have overlooked, particularly in times of market uncertainty. As of June 30, 2026, their Global Equity strategy manages $14.5 billion in assets. Also, check the fund's top five holdings to see its best picks in 2026.

In its second-quarter 2026 investor letter, Generation Investment Management Global Equity Strategy highlighted West Pharmaceutical Services, Inc. (NYSE: WST ). West Pharmaceutical Services, Inc. (NYSE:WST) is a leading manufacturer and distributor of containment and delivery systems for injectable drugs and healthcare products. On September 04, 2026, West Pharmaceutical Services, Inc. (NYSE:WST) closed at $339.97 per share, reflecting a market capitalization of $23.93 billion. West Pharmaceutical Services, Inc. (NYSE:WST) posted a one-month return of -3.45%, while its shares gained 34.30% over the past 52 weeks.

Generation Investment Management Global Equity Strategy stated the following regarding West Pharmaceutical Services, Inc. (NYSE:WST) in its Q2 2026 investor letter:

"West Pharmaceutical Services, Inc. (NYSE:WST): A West component represents only about 0.4% of the end cost of a finished drug – a trivial share. Yet if that component fails, the damage can be catastrophic. The classic illustration of this risk comes from the early 2000s. Organic compounds leached from rubber stoppers into a brand of erythropoietin, used to treat kidney disease, and patients developed immune reactions. To ensure this did not happen again, regulations on drug packaging were tightened significantly. West was the first company to come up with a solution. It offered 'inter-coated' packaging products (comprising a layer that sits between the drug and the rubber) that have since become the industry standard. Internally the company refers to this technology as its 'high-value products' (HVP). West represents around three quarters of this market – and, remarkably, that share is still growing, because it supplies more than 90% of newly approved drugs (in some years, every single one). It also has a near 100% share of GLP-1 drugs. In part for these reasons, we score West a 1 on our internal rating of Business Quality, the highest score we offer...." ( Click here to read the full text )

"West Pharmaceutical Services, Inc. (NYSE:WST): A West component represents only about 0.4% of the end cost of a finished drug – a trivial share. Yet if that component fails, the damage can be catastrophic. The classic illustration of this risk comes from the early 2000s. Organic compounds leached from rubber stoppers into a brand of erythropoietin, used to treat kidney disease, and patients developed immune reactions.

To ensure this did not happen again, regulations on drug packaging were tightened significantly. West was the first company to come up with a solution. It offered 'inter-coated' packaging products (comprising a layer that sits between the drug and the rubber) that have since become the industry standard. Internally the company refers to this technology as its 'high-value products' (HVP). West represents around three quarters of this market – and, remarkably, that share is still growing, because it supplies more than 90% of newly approved drugs (in some years, every single one). It also has a near 100% share of GLP-1 drugs. In part for these reasons, we score West a 1 on our internal rating of Business Quality, the highest score we offer...." ( Click here to read the full text )